{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:55:12Z","timestamp":1777420512132,"version":"3.51.4"},"reference-count":46,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T00:00:00Z","timestamp":1524355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2018,11]]},"abstract":"<jats:p>Objective: To describe the most current evidence for the use of direct-acting antivirals (DAAs) to treat hepatitis C along the pregnancy-pediatric continuum in the United States. Data Sources: The MEDLINE\/PubMed databases were searched (January 1995 to February 2018) for articles in English using the terms: hepatitis C, vertical transmission, pregnancy, pediatrics, ribavirin, interferon, direct acting antivirals, daclatasvir, dasabuvir, elbasvir, glecaprevir, grazoprevir, ledipasvir, ombitasvir, paritaprevir, pibrentasvir, simeprevir, sofosbuvir, and velpatasvir. Study Selection and Data Extraction: All relevant studies, meta-analyses, systematic reviews, guidelines, and review articles were evaluated for inclusion. References from pertinent articles were assessed for additional content that was not found during the initial search. Data Synthesis: The primary route of transmission for hepatitis C virus (HCV) in pediatric patients is vertical transmission (VT), with the rate estimated to be 5.8%. Screening for HCV during pregnancy is not routinely part of clinical care, and the data for the use of DAAs in pregnancy is limited. A significant number of infected infants will clear the HCV infection spontaneously, and ledipasvir\/sofosbuvir and sofosbuvir have recently been Food and Drug Administration approved for use in pediatric patients older than 12 years. Conclusions: Data to determine the best treatment point along the pregnancy-pediatric continuum are limited; however, given the lack of human data for use of DAAs during pregnancy, low rate of VT, high rate of spontaneous pediatric clearance, and recent approval of DAAs for pediatric patients, treatment of chronically infected children seems to be the optimal strategy currently.<\/jats:p>","DOI":"10.1177\/1060028018772181","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T03:45:42Z","timestamp":1524368742000},"page":"1152-1157","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?"],"prefix":"10.1177","volume":"52","author":[{"given":"Leigh","family":"Cervino","sequence":"first","affiliation":[{"name":"School of Pharmacy, University of Maryland, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M.","family":"Hynicka","sequence":"additional","affiliation":[{"name":"School of Pharmacy, University of Maryland, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2018,4,22]]},"reference":[{"key":"bibr1-1060028018772181","volume-title":"Global Hepatitis Report 2017","author":"World Health Organization","year":"2017"},{"key":"bibr2-1060028018772181","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"bibr3-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2005.10.031"},{"key":"bibr4-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318258328d"},{"key":"bibr5-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu447"},{"key":"bibr6-1060028018772181","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6528a2"},{"key":"bibr7-1060028018772181","unstructured":"Kentucky reportable disease regulations: 902 ky. admin. regs. 2:020. http:\/\/www.lrc.ky.gov\/kar\/902\/002\/020.htm."},{"key":"bibr8-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310328"},{"key":"bibr9-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24298"},{"key":"bibr10-1060028018772181","doi-asserted-by":"crossref","unstructured":"Aebi-Popp K, Duppenthaler A, Rauch A, De Gottardi A, Kahlert C. Vertical transmission of hepatitis C: towards universal antenatal screening in the era of new direct acting antivirals (DAAs)? Short review and analysis of the situation in Switzerland. J Virus Erad. 2016;2:52-54. http:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4946698\/. Accessed April 5, 2018.","DOI":"10.1016\/S2055-6640(20)30685-3"},{"key":"bibr11-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.430"},{"key":"bibr12-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.21480"},{"key":"bibr13-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1086\/497141"},{"key":"bibr14-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.02.082"},{"key":"bibr15-1060028018772181","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-4-200002150-00008"},{"key":"bibr16-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2005.05.003"},{"key":"bibr17-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpg.0000228117.52229.32"},{"key":"bibr18-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0b013e318170af04"},{"key":"bibr19-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2007.04859.x"},{"key":"bibr20-1060028018772181","unstructured":"American Association for the Study of Liver Diseases, Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. http:\/\/www.hcvguidelines.org\/. Accessed January15, 2017."},{"key":"bibr21-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2011.02556.x"},{"key":"bibr22-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2010.02218.x"},{"key":"bibr23-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2011.01436.x"},{"key":"bibr24-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2008.03.052"},{"key":"bibr25-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12430"},{"key":"bibr26-1060028018772181","unstructured":"Sovaldi (sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences Inc; 2017."},{"key":"bibr27-1060028018772181","unstructured":"Harvoni (ledipasvir and sofosbuvir) [package insert]. Foster City, CA: Gilead Sciences Inc; 2017."},{"key":"bibr28-1060028018772181","unstructured":"Technivie (ombitasvir, paritaprevir and ritonavir) [package insert]. North Chicago, IL: AbbVie Inc; 2017."},{"key":"bibr29-1060028018772181","unstructured":"Viekira XR (dasabuvir, ombitasvir, paritaprevir, and ritonavir) [package insert]. North Chicago, IL: AbbVie Inc; 2017."},{"key":"bibr30-1060028018772181","unstructured":"Zepatier (elbasvir and grazoprevir) [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2016."},{"key":"bibr31-1060028018772181","unstructured":"Mavyret (glecaprevir and pibrentasvir) [package insert]. North Chicago, IL: AbbVie Inc; 2017."},{"key":"bibr32-1060028018772181","unstructured":"Epclusa (sofosbuvir and velpatasvir) [package insert]. Foster City, CA: Gilead Sciences Inc; 2016."},{"key":"bibr33-1060028018772181","unstructured":"Daklinza (daclatasvir) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2017."},{"key":"bibr34-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20661"},{"key":"bibr35-1060028018772181","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v18.i2.99"},{"key":"bibr36-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.10.047"},{"key":"bibr37-1060028018772181","first-page":"185","volume":"19","author":"Zhang HF","year":"2005","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"bibr38-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318159836c"},{"key":"bibr39-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31654-0"},{"key":"bibr40-1060028018772181","volume":"16","author":"Pawlowska M","year":"2010","journal-title":"Med Sci Monit"},{"key":"bibr41-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.028"},{"key":"bibr42-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis1031"},{"key":"bibr43-1060028018772181","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i7.1098"},{"key":"bibr44-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199710000-00016"},{"key":"bibr45-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28995"},{"key":"bibr46-1060028018772181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29278"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018772181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028018772181","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028018772181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:25Z","timestamp":1777374865000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028018772181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,22]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.1177\/1060028018772181"],"URL":"https:\/\/doi.org\/10.1177\/1060028018772181","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,22]]}}}